Epic Sciences mission is to improve patient lives by enabling precision medicine and personalize treatments.
To accomplish our mission, we are using our proprietary circulating tumor cell (CTC) detection platform to develop predictive tests of therapy benefit. These tests will provide essential information to physicians, helping them guide treatment decisions to extend patient lives. These tests are being developed in our Clinical Laboratory (CLIA ID: 05D2087488).
JUST RELEASED: Study from MSK and Epic Sciences shows only nuclear-localized AR-V7 is predictive of therapy benefit for patients with metastatic prostate cancer.
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. European Urology. Scher et al, Eur. Assn of Urologoy. Online Publication. January 6, 2017. DOI:10.1016/j.eururo.2016.11.024